← Browse by Condition
Medical Condition

iparomlimab and tuvonralimab

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2
NCT07389629 Phase 2
Recruiting

Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Enrollment
25 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →